The FDA has granted orphan drug status to rilzabrutinib, an investigational therapy to prevent pain crises in sickle cell ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

Rilzabrutinib is a promising treatment option for patients with chronic spontaneous urticaria who are refractory to antihistamines.

Editor's note: Details about rilzabrutinib have been corrected in this article. Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval.

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...

Researchers conducted a phase 1/phase 2 open-label study to evaluate the efficacy and safety of rilzabrutinib (Sanofi) — reversible Bruton tyrosine kinase inhibitor — among adults with ...

The FDA granted Sanofi (SNY) US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a post to the agency’s website. Don't Miss Our End ...

Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib in patients with immune thrombocytopenia (ITP). Data from ...